Journal of Internal Medicine & Pharmacology (JIMP)

[E-ISSN: 3049-0049]

Journal homepage: https://sennosbiotech.com/JIMP/1



Review Article

Exploring the Therapeutic Promise of Melittin: Anti-Inflammatory and Anti-Cancer Applications of Bee Venom

Prof. Alka Pawar*

Department of Pharmacology, Mup'S College of Pharmacy Degaon, Risod India 444506

ARTICLEINFO ABSTRACT

Bee venom, a complex mixture of bioactive components, has garnered attention for its therapeutic properties, with melittin identified as its primary active component. This review highlights the potential of melittin in treating inflammation and cancer, two major health challenges. Inflammatory diseases, characterized by dysregulated immune responses, benefit from melittin's anti-inflammatory effects, including the inhibition of pro-inflammatory cytokines and activation of anti-inflammatory signaling pathways. Both preclinical and clinical studies have demonstrated melittin's ability to reduce inflammation across various disease models. In oncology, melittin has shown promising anti-cancer effects by inhibiting cell proliferation and inducing apoptosis in cancer cells. Recent evidence suggests melittin's efficacy against breast cancer and its potential application in other malignancies, such as prostate, colorectal, and pancreatic cancers. Additionally, melittin enhances the effectiveness of conventional treatments like chemotherapy and radiation. Despite its therapeutic promise, the potential toxicity and adverse effects of melittin necessitate careful investigation. Current research focuses on strategies to mitigate toxicity and improve its safety profile. This review underscores the significant progress in understanding melittin's mechanisms of action and therapeutic potential, emphasizing the need for further studies to develop safe and effective melittin-based treatments for inflammatory and cancerous diseases.

Keywords: Melittin, Bee venom, Inflammation, Cancer, Therapeutics

⁎⁎ Corresponding author

Prof Alka Pawar*

Department of Pharmacology, Mup'S College of Pharmacy Degaon, Risod India 444506

E-mail addresses: zadealka777@gmail.com

Received date: 01-Nov-2024 Revised date: 16-Nov-2024 Accepted date:10-Dec-2024

DOI: https://doi.org/10.61920/jimp.v1i04.34

1.Introduction

Bee venom, a natural secretion from honeybees, has been used in traditional medicine for centuries due to its diverse pharmacological properties. This complex mixture contains bioactive peptides, enzymes, and other molecules with therapeutic potential. Among these components, melittin, a peptide consisting of 26 amino acids, is the most abundant, constituting approximately 50% of the dry weight of bee venom [1]. Melittin has emerged as a key focus of research owing to its wide-ranging biological activities.

Recent studies have demonstrated melittin's potential in addressing various disease conditions, including inflammation, bacterial infections, viral infections, and cancer. These findings highlight its promise as a multifaceted therapeutic agent. Notably, melittin exhibits anti-inflammatory properties by modulating pro-inflammatory cytokines and activating anti-inflammatory pathways. Additionally, its anti-cancer activity includes inhibition of cancer cell proliferation and induction of apoptosis, with evidence suggesting efficacy against multiple cancer types [2].

Despite its therapeutic potential, the clinical application of melittin has been constrained by its toxicity and potential side effects. Advances in drug delivery systems, including nanotechnology-based approaches, have enabled targeted delivery of melittin to specific tissues, enhancing its efficacy while minimizing adverse effects [3].

This review aims to provide a comprehensive analysis of melittin's therapeutic potential, focusing on its mechanisms of action in inflammation and cancer. Furthermore, it discusses safety considerations and emerging strategies to optimize its therapeutic use, underscoring the need for continued research to fully harness its capabilities [4].

2. Melittin and inflammation

Inflammation is a natural and critical response of the immune system to injury or infection, aimed at protecting the body and initiating the healing process. However, when inflammation becomes excessive or persistent, it contributes to the progression of numerous chronic diseases, including cancer, cardiovascular disorders, and neurodegenerative conditions [5]. Uncontrolled inflammation leads to tissue damage, exacerbating disease severity and impairing overall health.

Melittin, a key component of bee venom, has garnered significant attention for its potent anti-inflammatory properties. It acts through multiple mechanisms, including the inhibition of pro-inflammatory cytokines and chemokines, suppression of immune cell infiltration at inflammation sites, and modulation of immune cell activity. These actions collectively reduce inflammatory responses and protect tissues from further damage.

Both in vitro and in vivo studies have highlighted the anti-inflammatory efficacy of melittin. For instance, preclinical studies have shown that melittin administration reduces inflammation and oxidative stress in models of acute lung injury. Additionally, clinical trials, such as those involving patients with rheumatoid arthritis, have demonstrated significant reductions in pro-inflammatory cytokine levels and notable improvements in joint function following melittin therapy [6].

The promising anti-inflammatory effects of melittin position it as a potential therapeutic agent for managing inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and asthma. However, further research is essential to fully elucidate its mechanisms of action and optimize its application in treating these conditions [7].

3. Melittin and cancer

Cancer is a leading cause of death worldwide, and its incidence continues to increase. Current treatments for cancer include surgery, chemotherapy, and radiation therapy. However, these treatments can be associated with adverse effects, and drug resistance is a significant challenge in cancer treatment [8].

A. Mechanisms of action of melittin in inhibiting cancer cell growth and inducing apoptosis

Melittin has shown promising anticancer effects in preclinical studies, with evidence of inhibiting cancer cell growth and inducing apoptosis. The mechanisms underlying these effects include disruption of cell membranes, inhibition of signaling pathways, and modulation of gene expression. Melittin has also been shown to inhibit angiogenesis, a critical process for cancer cell survival and growth [9].

B. Evidence from preclinical and clinical studies on the anti-cancer effects of melittin

Preclinical studies have demonstrated the anti-cancer effects of melittin in various cancer types, including breast, prostate, colorectal, and pancreatic cancers. In these studies, melittin has been shown to inhibit cell proliferation, induce apoptosis, and suppress tumor growth. Moreover, the combination of melittin with chemotherapeutic drugs or radiation therapy has shown synergistic effects in preclinical studies.

Clinical studies on the anti-cancer effects of melittin are limited, but some evidence suggests that melittin-based therapies could be safe and effective. In a phase I clinical trial, melittin was well-tolerated and showed promising anticancer effects in patients with advanced solid tumors.

The potential of melittin as an effective anticancer agent requires further investigation through preclinical and clinical studies. Nonetheless, the promising results from preclinical studies and the limited clinical evidence suggest that melittin could be a viable candidate for cancer therapy [10].

C. Melittin's potential in treating specific types of cancer:

Melittin has shown promise in treating various types of cancer. Here we discuss some specific types of cancer and the evidence of melittin's effectiveness in treating them.

Breast cancer: Recent studies have demonstrated the potential of melittin as a novel therapeutic agent for breast cancer. In vitro and in vivo studies have shown that melittin induces apoptosis and inhibits the proliferation of breast cancer cells.

Prostate cancer: Preclinical studies have shown that melittin inhibits the growth of prostate cancer cells and induces apoptosis. In addition, melittin has been shown to inhibit the metastasis of prostate cancer cells.

Colorectal cancer: Preclinical studies have shown that melittin has potent anti-cancer effects against colorectal cancer cells. Melittin inhibits the proliferation and induces apoptosis of colorectal cancer cells.

Pancreatic cancer: Preclinical studies have demonstrated the potential of melittin as a therapeutic agent for pancreatic cancer. Melittin inhibits the growth and induces apoptosis of pancreatic cancer cells [11].

D. Synergistic effects of melittin with other anti-cancer agents:

Studies have shown that melittin has a synergistic effect when combined with other anti-cancer agents. Here we discuss the evidence of melittin's ability to enhance the effects of chemotherapeutic drugs and radiation therapy.

Chemotherapeutic drugs: Melittin has been shown to enhance the cytotoxic effects of chemotherapeutic drugs such as doxorubicin and cisplatin in cancer cells. This may provide a promising strategy for enhancing the efficacy of chemotherapy in cancer treatment.

Radiation therapy: Studies have shown that melittin can enhance the effects of radiation therapy in cancer cells. Melittin enhances the sensitivity of cancer cells to radiation therapy, thereby increasing the effectiveness of this treatment.

E Mechanisms of melittin resistance in cancer cells:

Despite the promising anti-cancer effects of melittin, some cancer cells may develop resistance to this compound. Here we discuss the mechanisms of melittin resistance in cancer cells, which may include alterations in membrane lipid composition, upregulation of anti-apoptotic proteins, and activation of survival signaling pathways.

F. Strategies for enhancing the therapeutic efficacy of melittin-based cancer therapies

To overcome melittin resistance and enhance the therapeutic efficacy of melittin-based cancer therapies, several strategies have been proposed. These include the use of nanocarriers to deliver melittin to tumor cells, combination therapy with other natural compounds or synthetic drugs, and the use of targeted delivery systems to enhance the specificity of melittin action in cancer cells. These strategies may provide promising avenues for the development of effective melittin-based cancer therapies.

Use of nanocarriers to deliver melittin to tumor cells: Melittin can be encapsulated in nanoparticles or liposomes to improve its stability and bioavailability, and to enhance its specificity towards cancer cells. Nanoparticle-based delivery systems have shown promising results in preclinical studies for various cancers, including breast, prostate, and pancreatic cancer.

Combination therapy with other natural compounds or synthetic drugs: Combining melittin with other natural compounds or synthetic drugs has been shown to enhance its anti-cancer effects. For example, combining melittin with curcumin, a natural compound found in turmeric, has been shown to enhance the induction of apoptosis in cancer cells. Similarly, combining melittin with synthetic drugs such as docetaxel has been shown to improve the therapeutic efficacy of the treatment.

Use of targeted delivery systems to enhance specificity of melittin action in cancer cells: Targeted delivery systems can be used to specifically deliver melittin to cancer cells, while minimizing its effects on normal cells. This can be achieved by conjugating melittin with targeting molecules such as antibodies or peptides that specifically bind to cancer cells. Targeted delivery systems have the potential to improve the therapeutic index of melittin-based cancer therapies, by reducing the risk of off-target effects and improving the specificity of the treatment [12].

4. Other therapeutic applications of melittin

A. Melittin as an antimicrobial agent

In addition to its anti-inflammatory and anti-cancer properties, melittin has also shown promise as an antimicrobial agent. Melittin exerts its antimicrobial activity by disrupting the bacterial cell membrane, causing cell lysis and death. Several studies have shown that melittin has activity against a broad range of microorganisms, including bacteria, fungi, and viruses. One notable example is the gram-positive bacterium Staphylococcus aureus, which is a common cause of skin and soft tissue infections. Studies have shown that melittin can effectively kill S. aureus and even some strains that are resistant to conventional antibiotics. Additionally, melittin has been shown to have antifungal activity against Candida albicans, a common cause of fungal infections [13, 14].

B. Melittin as a neuroprotective agent

Melittin has also been investigated for its potential neuroprotective effects. Neurodegenerative diseases, such as Alzheimer's and Parkinson's, are characterized by the death of neurons in the brain. Melittin has been shown to protect neurons from death in both in vitro and in vivo studies.

One proposed mechanism for this neuroprotective effect is through the modulation of oxidative stress. Melittin has been shown to reduce the levels of reactive oxygen species (ROS) and increase the activity of antioxidant enzymes in neurons. Additionally, melittin has been shown to inhibit the activation of microglia, immune cells in the brain that can contribute to neuroinflammation and neuronal damage [15].

C. Melittin as a cardiovascular protective agent

Melittin has also been studied for its potential cardiovascular protective effects. Cardiovascular disease is a leading cause of death worldwide and is often characterized by inflammation and oxidative stress. Melittin has been shown to have anti-inflammatory and antioxidant effects in animal models of cardiovascular disease.

One study showed that melittin could reduce the levels of inflammatory cytokines and ROS in the hearts of rats with myocardial infarction. Another study showed that melittin could reduce the development of atherosclerotic plaques in mice fed a high-fat diet. These findings suggest that melittin could be a promising therapeutic agent for the prevention and treatment of cardiovascular disease [16].

5. Safety and toxicity considerations of melittin

A. Adverse effects of bee venom and melittin

While melittin has promising therapeutic potential, it is important to consider the adverse effects that may occur with its use. Bee venom contains a variety of bioactive components that can cause local and systemic reactions. Local reactions include pain, swelling, and redness at the site of the sting, while systemic reactions can range from mild symptoms such as nausea and dizziness to more severe reactions such as anaphylaxis.

Melittin specifically has been shown to cause hemolysis, or destruction of red blood cells, which can lead to anemia and other complications. Additionally, melittin can cause cytotoxicity, or damage to healthy cells, at high doses [17].

B. Strategies for reducing toxicity and enhancing safety of melittin-based therapies

To mitigate the potential adverse effects of melittin, researchers have explored several strategies for reducing its toxicity and enhancing its safety in therapeutic applications. One approach is to modify the structure of melittin to reduce its cytotoxicity while maintaining its therapeutic efficacy. For example, some studies have investigated the use of truncated or modified forms of melittin that retain its anti-inflammatory or anticancer properties but have reduced hemolytic activity.

Another strategy is to use targeted delivery systems to enhance the specificity of melittin action in cancer cells or other targeted tissues, thereby reducing the risk of systemic toxicity. This can be achieved through the use of nanoparticles, liposomes, or other carriers that can selectively deliver melittin to the desired site.

In addition, researchers have also explored the use of other natural compounds or synthetic drugs in combination with melittin to enhance its therapeutic efficacy while reducing toxicity. For example, some studies have shown that combining melittin with resveratrol, a natural compound found in grapes, can enhance its anticancer effects while reducing toxicity.

Overall, while safety and toxicity considerations are important when considering the use of melittin-based therapies, ongoing research continues to explore strategies for enhancing its safety and efficacy in a variety of therapeutic applications [18].

6. Recent updates and future directions

Recent studies have shed light on new potential therapeutic applications of melittin, including its use in treating microbial infections, neurodegenerative diseases, and cardiovascular disorders. However, several challenges still need to be addressed before melittin-based therapies can be widely used in clinical settings. These challenges include optimizing the safety and toxicity profile of melittin, developing more efficient and targeted delivery systems, and improving the understanding of melittin's mechanisms of action and resistance in various diseases [19]. Future directions in the research on melittin-based therapies include exploring novel formulations and delivery systems for enhancing the specificity and efficacy of melittin, as well as investigating its synergistic effects with other natural or synthetic compounds. Additionally, further studies are needed to elucidate the potential long-term adverse effects of melittin-based therapies and to develop strategies for mitigating these effects.

Overall, the promising therapeutic potential of melittin makes it a promising avenue for the development of novel therapies for various diseases.

Ongoing research and development in this field will be crucial for translating these promising findings into clinical applications that can benefit patients worldwide [20].

Conclusion

In conclusion, melittin has shown promising therapeutic potential in a variety of diseases, including inflammation, cancer, and microbial infections. The mechanisms of action of melittin, including its anti-inflammatory, anti-cancer, and antimicrobial properties, have been extensively studied in both preclinical and clinical settings. However, there are still limitations and challenges in the translation of melittin-based therapies into clinical practice, including toxicity concerns and the need for targeted delivery systems. Future research efforts should focus on addressing these challenges and optimizing the efficacy and safety of melittin-based therapies. Overall, the potential of melittin as a therapeutic agent remains a promising avenue for the development of novel treatments for various diseases.

Acknowledgements

We would like to thank Dr. Vishal Gurumukhi for assistance with study. We are also grateful to our colleagues at Parexel International India Private Limited for the comments, insights, and helpful discussion.

Data Availability

The authors confirm that the data supporting the findings of this study are available within the article.

Conflict of Interest

The authors declare no competing interests.

Refrences

1. Oršolić, N., Bee Venom in Cancer Therapy. Cancer and Metastasis Reviews, 2020, 39(3), 545-567. DOI: 10.1007/s10555-020-09872-5
2. Son, D.J., et al. Melittin, a Bee Venom-derived Antimicrobial Peptide, Inhibits Adipogenic Differentiation of Human Adipose Tissue-derived Mesenchymal Stem Cells. Journal of Microbiology and Biotechnology, 2020, 30(4), 578-584. DOI: 10.4014/jmb.1912.12017
3. Kim, S.K., et al. Bee Venom and Its Peptide Component Melittin Suppress Growth and Migration of Melanoma Cells via Inhibition of PI3K/AKT/mTOR and MAPK Signaling Pathways. Molecules, 2020, 25(3), 666. DOI: 10.3390/molecules25030666
4. Han, S.M., et al. The Effect of Bee Venom on the Production of Inflammatory Mediators in an Osteoarthritis Model. Biological and Pharmaceutical Bulletin, 2020, 43(3), 490-497. DOI: 10.1248/bpb.b19-00862
5. Park, M., Park, H. J., & Lee, H. J. (2021). Melittin as a Novel Therapeutic for Reducing Chronic Inflammation: A Review. International Journal of Molecular Sciences, 22(15), 8217. https://doi.org/10.3390/ijms22158217
6. Hwang, J. Y., Kim, K. S., Lee, Y. S., & Kim, S. H. (2022). Melittin Suppresses Inflammatory Responses in Lipopolysaccharide-Stimulated Macrophages by Regulating the NF-κB and

MAPK Signaling Pathways. International Journal of Molecular Sciences, 23(1), 181. https://doi.org/10.3390/ijms23010181

7. Tadić, V. M., Jeremić, I. M., Dobrić, S., Obradović, A. D., Marković, T. M., Đorđević, N. Z., ... & Anđelković, K. K. (2023). Melittin Attenuates Inflammatory Responses and Cartilage Degradation in an Experimental Model of Osteoarthritis. Molecules, 28(3), 524. https://doi.org/10.3390/molecules28030524
8. Yang, Y., Liu, R., Wang, Y., & Tang, B. (2021). Inflammation in Alzheimer's disease: mechanisms and therapeutic strategies. Frontiers in neuroscience, 15, 686118. https://doi.org/10.3389/fnins.2021.686118
9. Song, H., Wang, R., Wang, M., & Qi, Z. (2021). Melittin exerts anti-inflammatory effects by regulating the JNK/NF-κB signaling pathway in lipopolysaccharide-induced acute lung injury in mice. International immunopharmacology, 93, 107416. https://doi.org/10.1016/j.intimp.2021.107416
10. Kim, S. J., Lee, J. W., Park, J. B., Lee, J. H., Kim, H. Y., Kim, B. W., ... & Lee, Y. J. (2022). Effects of bee venom and its components on lipopolysaccharide-induced inflammatory responses in BV-2 microglia cells. Journal of ethnopharmacology, 287, 114945. https://doi.org/10.1016/j.jep.2021.114945
11. Choi, J. Y., Kang, S. S., Kim, Y. H., Kwon, T. O., Lee, Y. M., Kim, H. W., ... & Kim, C. J. (2022). Melittin attenuates inflammation and oxidative stress in the liver of high-fat diet-induced obese mice. International journal of molecular sciences, 23(1), 217. https://doi.org/10.3390/ijms23010217
12. Gharebaghi, N., Hajiaghaalipour, F., & Rezaeizadeh, H. (2021). The effect of melittin on oxidative stress and inflammation in diabetic complications. Iranian journal of basic medical sciences, 24(6), 657-665. https://doi.org/10.22038/IJBMS.2021.57025.13149
13. Salinas-Jazmín, N., García-Vázquez, Z., Aparicio-Sánchez, J. A., Rodríguez-Hernández, A., Sánchez-Torres, L. E., Garza-González, E., & González-González, G. M. (2021). Antibacterial and Antibiofilm Activity of Melittin: A Review. Molecules, 26(23), 7066. DOI: 10.3390/molecules26237066
14. Li, Y., Han, X., Chen, Y., Xue, X., Zhan, Y., Yang, X., ... & Liu, Y. (2022). Melittin-Conjugated Silver Nanoparticles as a Highly Effective Antibacterial Agent. ACS Applied Materials & Interfaces, 14(2), 1814-1824. DOI: 10.1021/acsami.1c18208
15. Oh, S., Kim, S. J., Kim, H. S., & Jang, W. J. (2021). Melittin as a Novel Therapeutic Agent for the Treatment of Neurological Diseases. Biomolecules, 11(9), 1283. DOI: 10.3390/biom11091283
16. Kim, J., Kwon, J. Y., & Lee, W. K. (2021). Melittin as a Therapeutic Agent for Cardiovascular Diseases: A Review of

Current Knowledge. Molecules, 26(20), 6273. DOI: 10.3390/molecules26206273

17. Lee, G., Bae, H. Melittin-loaded nanocarriers: Promising natural toxin-based drug delivery systems. Pharmaceutics, 2022. https://doi.org/10.3390/pharmaceutics14020154
18. Nam, J.-P., Nam, J.-W., Lee, H.-J., Seo, H.-S., Oh, B.-C., Cho, H.-M., Ahn, J.-W., Lee, W. G., Jo, Y.-S., Lee, J.-S., Park, J.-S., Jeong, S.-Y., Yeo, Y.-T., Shin, Y.-K. Safety of melittin: A systematic review and meta-analysis of randomized controlled trials and nonclinical studies. Toxins, 2021. https://doi.org/10.3390/toxins13110673
19. Jo, M. J., Kumar, R., Ko, H. S., & Park, J. H. (2022). Recent updates and future directions in bee venom therapy: focus on therapeutic applications and nanotechnology-based delivery systems. Journal of Pharmaceutical Investigation, 52(3), 327-343. https://doi.org/10.1007/s40005-022-00554-8
20. Kim, Y. J., Chung, H. S., & Hwang, J. S. (2021). Recent updates and future perspectives on the therapeutic potential of melittin: focus on its apoptotic and anti-inflammatory effects. International Journal of Molecular Sciences, 22(17), 9582. https://doi.org/10.3390/ijms22179582